GeNeuro SA
http://www.geneuro.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeNeuro SA
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.
Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
GeNeuro Homes In On Ancestral Viral Genes To Treat Autoimmune Diseases
Focusing on an idea that many autoimmune diseases are caused by proteins from viral genes that are now embedded in human DNA, Swiss biotech GeNeuro is using the idea to develop therapeutics.
Pipeline Watch: Phase III Starts With Fasinumab, Varlitinib
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- GeNeuro Innovation SAS